What's in Johnson & Johnson Consumer Inc. (J&JCI)'s pipeline?

Johnson & Johnson Consumer Inc. (J&JCI) has 10 drugs in our index: 5 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Johnson & Johnson Consumer Inc. (J&JCI)'s portfolio?

Top competitors by shared drug class: C. R. Bard, Central DuPage Hospital, GlaxoSmithKline, Instituto de Investigacion Sanitaria La Fe, King Abdullah University Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/johnson-johnson-consumer-inc-j-jci.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Johnson & Johnson Consumer Inc. (J&JCI) — Portfolio Competitive Intelligence Brief

Johnson & Johnson Consumer Inc. (J&JCI) pipeline: 5 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 3 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Listerine Experimental Mouthwash	Listerine Experimental Mouthwash	marketed	Antimicrobial mouthwash		Oral Health / Dentistry
Listerine Clinical Solutions Teeth Strength	Listerine Clinical Solutions Teeth Strength	marketed	Oral rinse / topical fluoride product		Dental / Oral Health
LISTERINE COOL MINT Antiseptic Mouthwash	LISTERINE COOL MINT Antiseptic Mouthwash	marketed	Antiseptic mouthwash		Oral Health / Dentistry
Listerine Total Care Zero	Listerine Total Care Zero	marketed	Antimicrobial oral rinse		Oral Health / Dentistry
Antiseptic Wash	Antiseptic Wash	marketed	Topical antiseptic		Dermatology / Infection Prevention
F# 13418-148 Eye Drops	F# 13418-148 Eye Drops	phase 3			Ophthalmology
F# PF-004390 Eye Drops	F# PF-004390 Eye Drops	phase 3	TRPM8 antagonist	TRPM8	Ophthalmology
F#13418-158 Eye Drops	F#13418-158 Eye Drops	phase 3			Ophthalmology

Therapeutic area mix

Ophthalmology · 3
Oral Health / Dentistry · 3
Dental / Oral Health · 1
Dermatology / Infection Prevention · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

C. R. Bard · 1 shared drug class
Central DuPage Hospital · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Instituto de Investigacion Sanitaria La Fe · 1 shared drug class
King Abdullah University Hospital · 1 shared drug class
Poitiers University Hospital · 1 shared drug class
Professional Disposables International, Inc. · 1 shared drug class
Riyadh Elm University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Johnson & Johnson Consumer Inc. (J&JCI):

Cite this brief

Drug Landscape (2026). Johnson & Johnson Consumer Inc. (J&JCI) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/johnson-johnson-consumer-inc-j-jci. Accessed 2026-05-16.